Incorporation of microRNA expression in pharmacogenetic prediction models

将 microRNA 表达纳入药物遗传学预测模型

基本信息

批准号：
7776997
负责人：
Mary Eileen Dolan
金额：
$ 17.16万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-03-01 至 2012-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7776997
关键词：
ABCB1 gene Adverse event Adverse reactions Affect African Antimetabolites Ara-C Binding Biological Biology Candidate Disease Gene Carboplatin Categories Caucasians Caucasoid Race Cell Line Cells Cisplatin Clinical Research Clinical Trials Complex Cytotoxic agent Drops Drug Kinetics Drug toxicity European Exhibits Exons Figs - dietary Gene Expression Gene Expression Profiling Gene Frequency Gene Targeting Genes Genetic Genetic Markers Genetic Polymorphism Genetic Variation Genome Genotype Goals Human Human Genome In Vitro Individual Individual Differences International Laboratories Left Linear Regressions Messenger RNA Metabolism Methotrexate MicroRNAs Modeling Molecular Profiling Nigeria Normal Cell Ontology Pathway interactions Patients Pharmaceutical Preparations Pharmacodynamics Pharmacogenetics Pharmacogenomics Phase Phenotype Population Proteins Regression Analysis Reporting Resistance Risk Role Sampling Single Nucleotide Polymorphism Site Testing Toxic effect UGT1A1 gene Underserved Population Validation Variant antitumor agent arm base cancer therapy capecitabine cell growth chemotherapeutic agent chemotherapy cytotoxic cytotoxicity design drug efficacy drug sensitivity ethnic difference genetic pedigree genetic variant genome wide association study genome-wide irinotecan lymphoblastoid cell line mRNA Expression predictive modeling prevent protein structure public health relevance research clinical testing response trait tumor yellow-1

项目摘要

DESCRIPTION (provided by applicant): Most chemotherapeutic drugs affect both tumor and normal cells, are ineffective in a number of patients, and exhibit serious toxicity; hence developing predictive models that identify patients at risk for adverse reactions and/or non-response to chemotherapeutic agents prior to treatment is essential. An objective of this proposal is to take a concerted translational effort to elucidate the underlying cause for the inter-ethnic differences in sensitivity to chemotherapy. In this proposal, we will focus on two classes of cytotoxic agents: platinating agents (cisplatin and carboplatin) and antimetabolites (capecitabine and Ara-C), of which significant inter-ethnic differences in cellular sensitivity have been observed in vitro. Our hypothesis is that there are microRNA (miRNA) expression differences in individuals of African descent compared to individuals of European descent that contribute, at least in part, to the difference in sensitivity to chemotherapy-induced cytotoxicity in these two populations. Our long-term goal is to develop an unbiased genome-wide model to identify germline genetic variants, mRNA or miRNA expression including those in an underserved population, that predict risk for adverse reactions and non-response to chemotherapy. Our hypothesis is that there is a set of germline pharmacogenetic polymorphisms associated with the expression of miRNA that affect chemotherapy-induced cytotoxicity and these polymorphisms exhibit interethnic differences. Our specific aims are 1) To quantify genome-wide miRNA expression in HapMap lymphoblastoid cell lines (LCLs) and to identify SNPs associated with miRNA expression and chemotherapy-induced cytotoxicity; 2) To identify mRNA and miRNA expression signatures that significantly correlate with chemotherapy sensitivity and to compare the miRNA expression chemotherapeutic sensitivity signatures in different ethnic populations; 3) To replicate our findings in additional LCLs. PUBLIC HEALTH RELEVANCE: This proposal is intended to better understand how genetic variation contributes to individual sensitivity to chemotherapy. The long term goal is to identify patients, using their genetic make up, that are at risk for toxicities associated with chemotherapy with the intent to reduce their chances of an adverse event.

描述（申请人提供）：大多数化疗药物同时影响肿瘤和正常细胞，对许多患者无效，并表现出严重的毒性；因此，开发预测模型来识别治疗前有不良反应和/或对化疗药物无反应风险的患者至关重要。该提案的一个目标是采取协调一致的转化努力，阐明种族间化疗敏感性差异的根本原因。在本提案中，我们将重点关注两类细胞毒性药物：铂类药物（顺铂和卡铂）和抗代谢药物（卡培他滨和阿糖胞苷），在体外观察到其中细胞敏感性存在显着的种族间差异。我们的假设是，与欧洲血统个体相比，非洲血统个体存在 microRNA (miRNA) 表达差异，这至少部分导致了这两个人群对化疗诱导的细胞毒性敏感性的差异。我们的长期目标是开发一种公正的全基因组模型来识别种系遗传变异、mRNA 或 miRNA 表达，包括服务不足人群中的变异、mRNA 或 miRNA 表达，从而预测不良反应和化疗无反应的风险。我们的假设是，存在一组与影响化疗诱导的细胞毒性的 miRNA 表达相关的种系药物遗传学多态性，并且这些多态性表现出种族间差异。我们的具体目标是 1) 量化 HapMap 类淋巴母细胞系 (LCL) 中的全基因组 miRNA 表达，并鉴定与 miRNA 表达和化疗诱导的细胞毒性相关的 SNP； 2) 鉴定与化疗敏感性显着相关的mRNA和miRNA表达特征，并比较不同种族人群的miRNA表达化疗敏感性特征； 3) 在其他拼箱中复制我们的发现。公共卫生相关性：该提案旨在更好地了解遗传变异如何影响个体对化疗的敏感性。长期目标是利用患者的基因组成来识别有化疗相关毒性风险的患者，以减少发生不良事件的机会。